Cyclacel Pharmaceuticals Reports Material Definitive Agreement
Ticker: BGMSP · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1130166
| Field | Detail |
|---|---|
| Company | Cyclacel Pharmaceuticals, INC. (BGMSP) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $7.65, $9.00, $10.20 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
Related Tickers: CYCC
TL;DR
Cyclacel signed a big deal, details TBD.
AI Summary
Cyclacel Pharmaceuticals, Inc. filed an 8-K on September 2, 2025, reporting a material definitive agreement. The filing does not contain specific details about the agreement, dollar amounts, or parties involved, but it indicates a significant event for the company.
Why It Matters
This filing signals a potentially significant development for Cyclacel Pharmaceuticals, Inc., which could impact its business operations, financial standing, or strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- September 1, 2025 (date) — Earliest event reported
- September 2, 2025 (date) — Date of report
FAQ
What is the nature of the material definitive agreement reported by Cyclacel Pharmaceuticals, Inc.?
The filing does not specify the nature of the material definitive agreement.
Who are the parties involved in this material definitive agreement?
The filing does not disclose the names of the parties involved in the agreement.
Are there any financial terms or dollar amounts associated with this agreement?
The filing does not provide any specific financial terms or dollar amounts related to the agreement.
When did the earliest event related to this agreement occur?
The earliest event reported in relation to this agreement occurred on September 1, 2025.
What is the primary business of Cyclacel Pharmaceuticals, Inc.?
Cyclacel Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations (SIC code 2834).
Filing Stats: 896 words · 4 min read · ~3 pages · Grade level 11.6 · Accepted 2025-09-02 06:02:27
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CYCC The Nasdaq Capital M
- $7.65 — of the Company at an exercise price of $7.65 per share with an expiration date five
- $9.00 — of the Company at an exercise price of $9.00 per share with an expiration date five
- $10.20 — of the Company at an exercise price of $10.20 per share with an expiration date five
Filing Documents
- form8-k.htm (8-K) — 47KB
- ex10-1.htm (EX-10.1) — 102KB
- ex10-2.htm (EX-10.2) — 102KB
- ex10-3.htm (EX-10.3) — 102KB
- form8-k_001.jpg (GRAPHIC) — 7KB
- 0001641172-25-026110.txt ( ) — 640KB
- cycc-20250901.xsd (EX-101.SCH) — 4KB
- cycc-20250901_def.xml (EX-101.DEF) — 26KB
- cycc-20250901_lab.xml (EX-101.LAB) — 36KB
- cycc-20250901_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 1, 2025 Cyclacel Pharmaceuticals, Inc. By: /s/ Datuk Dr. Doris Wong Sing Ee Name: Datuk Dr. Doris Wong Sing Ee Title: Chief Executive Officer and Executive Director 3